当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.

Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.

Abstract：

:Arsenic trioxide (ATO) induces disease remission in acute promyelocytic leukemia (APL) patients, but not in non-APL acute myeloid leukemia (AML) patients. ATO at therapeutic concentrations (1-2 μM) induces APL NB4, but not non-APL HL-60, cells to undergo apoptosis through the mitochondrial pathway. The role of antiapoptotic protein Mcl-1 in ATO-induced apoptosis was determined. The levels of Mcl-1 were decreased in NB4, but not in HL-60, cells after ATO treatment through proteasomal degradation. Both glycogen synthase kinase-3β (GSK-3β) inhibitor SB216763 and siRNA blocked ATO-induced Mcl-1 reduction as well as attenuated ATO-induced apoptosis in NB4 cells. Silencing Mcl-1 sensitized HL-60 cells to ATO-induced apoptosis. Both ERK and AKT inhibitors decreased Mcl-1 levels and enhanced ATO-induced apoptosis in HL-60 cells. Sorafenib, an Raf inhibitor, activated GSK-3β by inhibiting its phosphorylation, decreased Mcl-1 levels and decreased intracellular glutathione levels in HL-60 cells. Sorafenib plus ATO augmented reactive oxygen species production and apoptosis induction in HL-60 cells and in primary AML cells. These results indicate that ATO induces Mcl-1 degradation through activation of GSK-3β in APL cells and provide a rationale for utilizing ATO in combination with sorafenib for the treatment of non-APL AML patients.

journal_name

Leukemia

journal_title

Leukemia

authors

Wang R,Xia L,Gabrilove J,Waxman S,Jing Y

doi

10.1038/leu.2012.180

subject

Has Abstract

pub_date

2013-02-01 00:00:00

pages

315-24

issue

2

eissn

0887-6924

issn

1476-5551

pii

leu2012180

journal_volume

27

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes.

    abstract：:B-cell chronic lymphocytic leukaemia (B-CLL) is a slowly progressing malignancy of CD5(+) B cells, for which at present no curative treatment is available. In our current study, we apply a novel bridging reagent to redirect cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) to target B-CLL. A streptavidin-fu...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404185

    authors： Mous R,Savage P,Remmerswaal EB,van Lier RA,Eldering E,van Oers MH

    更新日期：2006-06-01 00:00:00

  • Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.

    abstract：:In this study, the long-term outcome of 1818 patients treated in five consecutive clinical trials (the cooperative study group for childhood acute lymphoblastic leukaemia (COALL) 82, 85, 89, 92 and 97) from 24 cooperating centres in Germany is reported. The probability of event-free survival (pEFS) improved significan...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：10.1038/leu.2009.249

    authors： Escherich G,Horstmann MA,Zimmermann M,Janka-Schaub GE,COALL study group.

    更新日期：2010-02-01 00:00:00

  • Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells.

    abstract：:Cellular stressors induce various outcomes including inhibition of cell proliferation and cell death. Sodium salicylate (SA), a plant stress hormone, can suppress the proliferation or cause apoptosis in certain mammalian cancer cells. Plant stress hormones are activators of cellular responses, including cell death, to...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402419

    authors： Fingrut O,Flescher E

    更新日期：2002-04-01 00:00:00

  • Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.

    abstract：:Spliceosome mutations represent a new generation of acquired genetic alterations that affect both myeloid and lymphoid malignancies. A substantial proportion of patients with myelodysplastic syndromes (MDSs) or chronic lymphocytic leukemia (CLL) harbor such mutations, which are often missense in type. Genotype-phenoty...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2012.86

    authors： Damm F,Nguyen-Khac F,Fontenay M,Bernard OA

    更新日期：2012-09-01 00:00:00

  • Cancer from the perspective of stem cells and misappropriated tissue regeneration mechanisms.

    abstract：:Tumorigenesis can be considered as pathologically misappropriated tissue regeneration. In this review we will address some unresolved issues that support this concept. First, we will address the issue of the identity of cancer-initiating cells and the presence of cancer stem cells in growing tumors. We will also ask a...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-018-0294-7

    authors： Ratajczak MZ,Bujko K,Mack A,Kucia M,Ratajczak J

    更新日期：2018-12-01 00:00:00

  • Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group.

    abstract：:The Brazilian Cooperative Group for Treatment of Childhood Acute Lymphocytic Leukemia (GBTLI) has started clinical activities trials in 1980. Three consecutive multicenter studies in children with unprevious treated ALL have been completed including 994 patients. The first GBTLI-80 accrued 203 children from 1980 to 19...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Brandalise S,Odone V,Pereira W,Andrea M,Zanichelli M,Aranega V

    更新日期：1993-08-01 00:00:00

  • Reconstitution of functional human GM-CSF receptor in mouse NIH3T3 fibroblasts and BA/F3 proB cells.

    abstract：:Granulocyte-macrophage colony-stimulating factor (GM-CSF) plays a critical role in growth and differentiation of myeloid cells. We previously reconstituted high affinity human GM-CSF receptor (hGM-CSFR) in a proB cell line BA/F3 by cotransfecting alpha and beta chain cDNA clones and showed that the reconstituted recep...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Yokota T,Watanabe S,Mui AL,Muto A,Miyajima A,Arai K

    更新日期：1993-08-01 00:00:00

  • Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

    abstract：:We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL). Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of flt3 was observed in 61 patients; 22 (73%) with AML and 39 (78%) with ALL. Among these, five patien...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Nakao M,Yokota S,Iwai T,Kaneko H,Horiike S,Kashima K,Sonoda Y,Fujimoto T,Misawa S

    更新日期：1996-12-01 00:00:00

  • Essential thrombocythemia--clinical features, therapy and follow-up of 12 cases.

    abstract：:The authors analyzed twelve patients with symptomatic essential throthrombocythemia (E.T.) diagnosed from 1983 to 1991. Haemorrhagic and thrombotic phenomena were the main presenting features. Treatment consisted mostly of alpha-interferon (IFN-alpha 2b) subcutaneously in dosage ranging from 3 to 5 MU/m2 and hydroxyur...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Lopes E,Ribeiro MM,Silva MJ,Gandra M,Principe F,Granato C

    更新日期：1992-01-01 00:00:00

  • A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.

    abstract：:To guide development of new clinical strategies, a review of recent investigations in the pathobiology of MDS was performed. Articles were identified through a Medline search. Studies, including reviews, are cited in the references. A multistep pathogenesis is proposed. (1) Targeted injury or mutation within hemopoiet...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2401618

    authors： Rosenfeld C,List A

    更新日期：2000-01-01 00:00:00

  • Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes.

    abstract：:The MDM2 gene is a gene whose product binds to p53 and regulates its function. Amplification of MDM2 has been found in human sarcomas, where it leads to inactivation of p53. In 64 cases of generally advanced myelodysplastic syndromes, we found no amplification or rearrangement of MDM2 gene by Southern analysis. MDM2 R...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Preudhomme C,Quesnel B,Vachee A,Lepelley P,Collyn-D'Hooghe M,Wattel E,Fenaux P

    更新日期：1993-08-01 00:00:00

  • Stimulation of leukemic myelopoiesis by P30-35 CAMAL, an inhibitor of normal myelopoiesis.

    abstract：:CAMAL (common antigen in myelogenous acute leukemia) is an antigenic preparation isolated in this laboratory from the bone marrow or peripheral blood cells of persons with myeloid leukemias and shown in an immunoperoxidase slide test to be diagnostic of these leukemias. CAMAL has been shown to be inhibitory to myelopo...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Leitch HA,Buskard N,Levy JG

    更新日期：1993-09-01 00:00:00

  • Do CLL B cells correspond to naive or memory B-lymphocytes? Evidence for an active Ig switch unrelated to phenotype expression and Ig mutational pattern in B-CLL cells.

    abstract：:Recent work suggests that chronic lymphocytic leukemia (B-CLL) expressing unmutated immunoglobulin V genes could correspond to the proliferation of naive B cells whereas those expressing mutated genes, may correspond to the proliferation of post-germinal center B cells. Current data from gene profiling expression have...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402731

    authors： Oppezzo P,Magnac C,Bianchi S,Vuillier F,Tiscornia A,Dumas G,Payelle-Brogard B,Ajchenbaum-Cymbalista F,Dighiero G,Pritsch O

    更新日期：2002-12-01 00:00:00

  • The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation.

    abstract：:Hematopoietic stem cell transplantation is becoming an increasingly important approach to treatment of different malignant and non-malignant disorders. There is thus growing demand for diagnostic assays permitting the surveillance of donor/recipient chimerism posttransplant. Current techniques are heterogeneous, rende...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.66

    authors： Lion T,Watzinger F,Preuner S,Kreyenberg H,Tilanus M,de Weger R,van Loon J,de Vries L,Cavé H,Acquaviva C,Lawler M,Crampe M,Serra A,Saglio B,Colnaghi F,Biondi A,van Dongen JJ,van der Burg M,Gonzalez M,Alcoceba M,Bar

    更新日期：2012-08-01 00:00:00

  • MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias.

    abstract：:Retroviral insertional mutagenesis in BXH2 mice commonly induces myeloid leukemias. One of the most frequently involved genes in experimental studies is Meis 1. In contrast to other genes in murine models, Meis 1 has not been affected by recurrent chromosomal translocations or point mutations in human leukemias. We fo...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403377

    authors： Lasa A,Carnicer MJ,Aventín A,Estivill C,Brunet S,Sierra J,Nomdedéu JF

    更新日期：2004-07-01 00:00:00

  • Quantitative analysis of Op18 phosphorylation in childhood acute leukemia.

    abstract：:Oncoprotein 18 (Op18) is a major cystolic phosphoprotein constituent of leukemia cells. There is cumulative evidence that suggests a role for Op18 in integrating signals from diverse pathways involved in cell growth. Op18 phosphorylation is induced with proliferation in a variety of cell types, and is essential for ce...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400792

    authors： Melhem R,Hailat N,Kuick R,Hanash SM

    更新日期：1997-10-01 00:00:00

  • Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.

    abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title：Leukemia

    pub_type： 已发布勘误

    doi：10.1038/s41375-020-0782-4

    authors： Weisberg E,Meng C,Case A,Sattler M,Tiv HL,Gokhale PC,Buhrlage S,Wang J,Gray N,Stone R,Liu S,Bhagwat SV,Tiu RV,Adamia S,Griffin JD

    更新日期：2020-09-01 00:00:00

  • Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

    abstract：:Because of their substantial in vitro synergy, we conducted a dose-escalation study of cyclophosphamide (CP) added to 2-chloro-2'-deoxyadenosine (CdA) in patients with previously treated chronic lymphocytic leukemia and non-Hodgkin's lymphoma. CdA was given at a fixed dose (5.6 mg/m2/day) as a 2-h intravenous (i.v.) i...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.leu.2401783

    authors： Van Den Neste E,Louviaux I,Michaux JL,Delannoy A,Michaux L,Sonet A,Bosly A,Doyen C,Mineur P,André M,Straetmans N,Coche E,Venet C,Duprez T,Ferrant A

    更新日期：2000-06-01 00:00:00

  • Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias.

    abstract：:There is increasing evidence that HOX homeobox genes play a role in leukemogenesis. Recent studies have demonstrated that enforced co-expression of HOXA9 and MEIS1 in murine marrow leads to rapid development of myeloid leukemia, and that these proteins exhibit cooperative DNA binding. However, it is unclear whether co...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401578

    authors： Lawrence HJ,Rozenfeld S,Cruz C,Matsukuma K,Kwong A,Kömüves L,Buchberg AM,Largman C

    更新日期：1999-12-01 00:00:00

  • Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

    abstract：:Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and rational treatment intervention strategies. Despite these significant advances there are still unanswered questions on patient management regarding how to more reliably predict treatment failur...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-019-0512-y

    authors： Branford S,Kim DDH,Apperley JF,Eide CA,Mustjoki S,Ong ST,Nteliopoulos G,Ernst T,Chuah C,Gambacorti-Passerini C,Mauro MJ,Druker BJ,Kim DW,Mahon FX,Cortes J,Radich JP,Hochhaus A,Hughes TP,International CML Foundation Ge

    更新日期：2019-08-01 00:00:00

  • RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.

    abstract：:Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)-dependent ubiquitylation and proteasome-dependent degradation of IKZF1 and IKZF3. A...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0403-2

    authors： Zhou N,Gutierrez-Uzquiza A,Zheng XY,Chang R,Vogl DT,Garfall AL,Bernabei L,Saraf A,Florens L,Washburn MP,Illendula A,Bushweller JH,Busino L

    更新日期：2019-08-01 00:00:00

  • CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

    abstract：:The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed "minimal residual disease". The phenomenon of disease persistence suggests that despite tar...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0684-5

    authors： Kinstrie R,Horne GA,Morrison H,Irvine D,Munje C,Castañeda EG,Moka HA,Dunn K,Cassels JE,Parry N,Clarke CJ,Scott MT,Clark RE,Holyoake TL,Wheadon H,Copland M

    更新日期：2020-06-01 00:00:00

  • The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.

    abstract：:Multiple myeloma is the second most frequent hematological cancer after lymphoma and remains an incurable disease. The pervasive support provided by the bone marrow microenvironment to myeloma cells is crucial for their survival. Here, an unbiased assessment of receptor tyrosine kinases overexpressed in myeloma identi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0486-9

    authors： Frenquelli M,Caridi N,Antonini E,Storti F,Viganò V,Gaviraghi M,Occhionorelli M,Bianchessi S,Bongiovanni L,Spinelli A,Marcatti M,Belloni D,Ferrero E,Karki S,Brambilla P,Martinelli-Boneschi F,Colla S,Ponzoni M,DePinho R

    更新日期：2020-01-01 00:00:00

  • Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.

    abstract：:Children with Down's syndrome (DS) have an increased risk of developing acute lymphoblastic leukemia (ALL) and have a low frequency of established genetic aberrations. We aimed to determine which genetic abnormalities are involved in DS ALL. We studied the frequency and prognostic value of deletions in B-cell developm...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.84

    authors： Buitenkamp TD,Pieters R,Gallimore NE,van der Veer A,Meijerink JP,Beverloo HB,Zimmermann M,de Haas V,Richards SM,Vora AJ,Mitchell CD,Russell LJ,Schwab C,Harrison CJ,Moorman AV,van den Heuvel-Eibrink MM,den Boer ML,Zwaan

    更新日期：2012-10-01 00:00:00

  • Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

    abstract：:We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B, and 14) between 1984 and 1999. The event-free survival improved significantly (P=0.003) from the first two trials conducted in the 1980s to the three more recent trials conducted in th...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：10.1038/leu.2009.252

    authors： Pui CH,Pei D,Sandlund JT,Ribeiro RC,Rubnitz JE,Raimondi SC,Onciu M,Campana D,Kun LE,Jeha S,Cheng C,Howard SC,Metzger ML,Bhojwani D,Downing JR,Evans WE,Relling MV

    更新日期：2010-02-01 00:00:00

  • Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.

    abstract：:Perturbation in iron homeostasis is a hallmark of some hematologic diseases. Abnormal sideroblasts with accumulation of iron in the mitochondria are named ring sideroblasts (RS). RS is a cardinal feature of refractory anemia with RS (RARS) and RARS with marked thrombocytosis (RARS/-T). Mutations in SF3B1, a member of ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.170

    authors： Visconte V,Avishai N,Mahfouz R,Tabarroki A,Cowen J,Sharghi-Moshtaghin R,Hitomi M,Rogers HJ,Hasrouni E,Phillips J,Sekeres MA,Heuer AH,Saunthararajah Y,Barnard J,Tiu RV

    更新日期：2015-01-01 00:00:00

  • Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.

    abstract：:As typical disorders of the elderly, myelodysplastic syndromes (MDSs) are relatively unusual in childhood. Nevertheless, up to 17% of cases of pediatric acute myeloid leukemia may have a preleukemic phase. In young patients, the goal of treatment is eradication of the preleukemic malignant clone and reconstitution of ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Locatelli F,Pession A,Bonetti F,Maserati E,Prete L,Pedrazzoli P,Zecca M,Prete A,Paolucci P,Cazzola M

    更新日期：1994-05-01 00:00:00

  • Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.

    abstract：:Bortezomib is a potent drug for the treatment of multiple myeloma. Its anti-tumor activity is mediated by proteasome inhibition leading to decreased cell proliferation and induction of apoptosis. However, an unimpaired proteasomal function plays a crucial role for the induction of anti-tumor immunity by dendritic cell...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404734

    authors： Straube C,Wehner R,Wendisch M,Bornhäuser M,Bachmann M,Rieber EP,Schmitz M

    更新日期：2007-07-01 00:00:00

  • Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

    abstract：:Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a ...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/leu.2016.299

    authors： Schlenk RF,Stegelmann F,Reiter A,Jost E,Gattermann N,Hebart H,Waller C,Hochhaus A,Platzbecker U,Schafhausen P,Blau IW,Verbeek W,Heidel FH,Werner M,Kreipe H,Teleanu V,Benner A,Döhner H,Grießhammer M,Döhner K

    更新日期：2017-04-01 00:00:00

  • ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.

    abstract：:Disruption of pathways leading to programmed cell death plays a major role in most malignancies, including multiple myeloma (MM). ABT-737 is a BH3 mimetic small-molecule inhibitor that binds with high affinity to Bcl-2 and Bcl-xL, preventing the sequestration of proapoptotic molecules and shifting the cell survival/ap...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404719

    authors： Kline MP,Rajkumar SV,Timm MM,Kimlinger TK,Haug JL,Lust JA,Greipp PR,Kumar S

    更新日期：2007-07-01 00:00:00